New AMG 479 Phase 2 Data Show Antitumor Activity in Patients With Metastatic Pancreatic Cancer

Friday, June 4, 2010 General News
Email Print This Page Comment
Font : A-A+

AMG 479 Extended Progression-Free Survival And Overall Survival Compared To Gemcitabine Alone

CONTACT: Amgen, Thousand Oaks

Leanne Madison: +1 (805) 603-9241 (media)

Arvind Sood: +1 (805) 447-1060 (investors)



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook